DL Life Logo - - - - 121,159 AMERICANS ARE CANDIDATES ON THE UNOS TRANSPLANT WAIT LIST DL Life Logo 100,376 waiting for a kidney DL Life Logo 14,753 wait-listed for a liver DL Life Logo 1,029 waiting for a pancreasDL Life Logo 1,924 needing a Kidney-PancreasDL Life Logo 4,156 waiting for a life-saving heartDL Life Logo 1,469 waiting for a lungDL Life Logo 42 waiting for a heart-lungDL Life Logo 269 waiting for small bowelDL Life Logo One organ donor has the opportunity to save up to 8 lives DL Life Logo One tissue donor has the opportunity to save and -or enhance the lives of 50 or more individuals DL Life Logo An average of 22 people die everyday while waiting for a transplant. DL Life Logo You have the power to SAVE Lives by becoming an organ, eye and tissue donor, so what are you waiting for? To learn how to register click HEREDL Life Logo

Tuesday, August 2, 2016

Natera and UCSF Initiate Collaboration to Study DNA Markers of Kidney Transplant Rejection

PR NEWSWIRE | Natera, Inc.

SAN CARLOS, Calif., Aug. 1, 2016 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, announced a research collaboration with the University of California, San Francisco (UCSF), a leader in renal transplantation medicine in North America, to study the level of donor-derived cell-free DNA (dd-cfDNA) in over several hundred retrospectively banked plasma samples from kidney transplant recipients with and without organ injury.

There is a significant unmet need for a more accurate non-invasive diagnostic test for renal transplant care. Currently, physicians rely on a combination of creatinine measures and invasive needle biopsies, which often result in inconclusive results or a diagnosis of acute rejection after the damage to the kidney is irreversible.

Multiple studies have shown dd-cfDNA has a potential to be a universal marker for acute rejection for solid organs. Under this research collaboration, Natera will analyze the dd-cfDNA level of plasma samples collected at UCSF from kidney transplant patients using Natera's proprietary massively-multiplexed PCR (mmPCR) platform and proprietary statistical algorithms. Through this research collaboration, Natera and UCSF will investigate whether the routine measurement of dd-cfDNA can help predict organ injury and ultimately improve clinical outcomes. Continue reading
_______________________________________________________________________
You have the power to SAVE Lives
Please register as an organ, eye and tissue donor today.
In California:
Donate LIFE California | Done VIDA California
Nationwide:
Organ Donor | Donate Life America

...to ensure donation happens, please share your donation decision with your family. At stake is the legacy you plan to leave.

No comments: